These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Saiman L; Chen Y; Tabibi S; San Gabriel P; Zhou J; Liu Z; Lai L; Whittier S J Clin Microbiol; 2001 Nov; 39(11):3942-5. PubMed ID: 11682511 [TBL] [Abstract][Full Text] [Related]
45. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. Campana S; Taccetti G; Ravenni N; Masi I; Audino S; Sisi B; Repetto T; Döring G; de Martino M J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902 [TBL] [Abstract][Full Text] [Related]
46. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. Martina P; Feliziani S; Juan C; Bettiol M; Gatti B; Yantorno O; Smania AM; Oliver A; Bosch A Int J Med Microbiol; 2014 Nov; 304(8):1182-91. PubMed ID: 25217078 [TBL] [Abstract][Full Text] [Related]
47. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. Valenza G; Tappe D; Turnwald D; Frosch M; König C; Hebestreit H; Abele-Horn M J Cyst Fibros; 2008 Mar; 7(2):123-7. PubMed ID: 17693140 [TBL] [Abstract][Full Text] [Related]
48. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Banerjee D; Stableforth D Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122 [TBL] [Abstract][Full Text] [Related]
49. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Horsley A; Jones AM Cochrane Database Syst Rev; 2012 Oct; 10():CD009529. PubMed ID: 23076960 [TBL] [Abstract][Full Text] [Related]
50. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. Krzewinski JW; Nguyen CD; Foster JM; Burns JL J Clin Microbiol; 2001 Oct; 39(10):3597-602. PubMed ID: 11574579 [TBL] [Abstract][Full Text] [Related]
51. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Hoyle N; Zhvaniya P; Balarjishvili N; Bolkvadze D; Nadareishvili L; Nizharadze D; Wittmann J; Rohde C; Kutateladze M Res Microbiol; 2018 Nov; 169(9):540-542. PubMed ID: 29777836 [TBL] [Abstract][Full Text] [Related]
52. Activity of airway antimicrobial peptides against cystic fibrosis pathogens. Cabak A; Hovold G; Petersson AC; Ramstedt M; Påhlman LI Pathog Dis; 2020 Oct; 78(7):. PubMed ID: 32857857 [TBL] [Abstract][Full Text] [Related]
55. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Govan JR; Brown AR; Jones AM Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652 [TBL] [Abstract][Full Text] [Related]
58. Isolation of infectious cystic fibrosis patients: results of a systematic review. Vonberg RP; Gastmeier P Infect Control Hosp Epidemiol; 2005 Apr; 26(4):401-9. PubMed ID: 15865277 [TBL] [Abstract][Full Text] [Related]
59. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. Dobbin C; Maley M; Harkness J; Benn R; Malouf M; Glanville A; Bye P J Hosp Infect; 2004 Apr; 56(4):277-82. PubMed ID: 15066737 [TBL] [Abstract][Full Text] [Related]